Skip to content
  • Home
  • IOncology
  • Infectious Desease Frontier
  • IHepatology
  • Hematology Frontier
  • Conference topics
  • Experts Interviews
  • Informations
  • Live Broadcasting
  • Logout
MediaMedic

Connecting Medical Expertise through Media

  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations
  • Home
  • IOncology
  • Infectious Disease Frontier
  • International Hepatology
  • Hematology Frontier
  • Conference topics
  • Experts’ Interviews
  • Informations

#ChronicHepatitisB

Home » #ChronicHepatitisB
AASLD’s Chinese Impact: Dr. Liang Peng’s Team Achieves Multiple Research Milestones in Chronic Hepatitis B and Related Liver Failure

AASLD’s Chinese Impact: Dr. Liang Peng’s Team Achieves Multiple Research Milestones in Chronic Hepatitis B and Related Liver Failure

Posted by By El Bachir MOURABIT 2024.12.03
From November 15-19, 2024, the 75th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) was held in San Diego, USA. At this prestigious event, Dr.…
Read More
JOH | Predictive Factors for Hepatitis Flares after Stopping Nucleos(t)ide Analogs

JOH | Predictive Factors for Hepatitis Flares after Stopping Nucleos(t)ide Analogs

Posted by By Peng Longmei 2024.09.17
According to the World Health Organization (WHO), approximately 296 million people globally suffer from chronic hepatitis B (CHB). Despite the advent of new therapies, long-term treatment with nucleos(t)ide analogs (NAs)…
Read More
Dr. Jie Li: Exploring and Prospects of Functional Cure for Chronic Hepatitis B

Dr. Jie Li: Exploring and Prospects of Functional Cure for Chronic Hepatitis B

Posted by By El Bachir MOURABIT 2024.09.08
Editor's Note: Achieving a functional cure for chronic hepatitis B (CHB) has become the recognized ideal treatment goal in both domestic and international guidelines, as it significantly reduces the risk…
Read More
Dr. Peng Hu’s Team: “Gray Zone” Patients Have a Higher Risk of Disease Progression than HBeAg-Negative HBV Infections

Dr. Peng Hu’s Team: “Gray Zone” Patients Have a Higher Risk of Disease Progression than HBeAg-Negative HBV Infections

Posted by By Mourabit Halima 2024.02.16
Currently, there is limited research on the natural history of disease in patients with chronic hepatitis B in the "gray zone," and there is still debate about the necessity of…
Read More
APASL 2023 | Prof. Wu Chao: Metabolic Predictors and Liver Fibrosis Diagnostic Model Construction for Chronic Hepatitis B Combined with NAFLD

APASL 2023 | Prof. Wu Chao: Metabolic Predictors and Liver Fibrosis Diagnostic Model Construction for Chronic Hepatitis B Combined with NAFLD

Posted by By Mourabit Halima 2024.01.03
Editor's Note: Chronic hepatitis B (CHB) is the primary cause of chronic liver disease in China and other Asian countries, as well as a major contributor to liver-related morbidity and…
Read More
Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B

Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B

Posted by By Peter W. PENG 2023.12.21
Chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) are both significant contributors to liver-related complications and mortality. Dr. Youwen Tan's team at the Third People's Hospital of Jiangsu…
Read More
Recent Posts
  • 2026 Pujiang Urological Oncology Academic Conference丨Chunguang Ma: Immunotherapy Opens a New Era in Adjuvant Treatment for Urothelial Carcinoma—From a Shift in Perioperative Concepts to Precision Whole-Course Management
  • Professor Yongmei Yin: Advancing Precision Oncology from Concept to Clinical Practice — Key Insights from the 2026 “Renyi” Clinical Research Conference on Innovative Anticancer Drugs
  • 2026 Northern Breast Cancer Salon · Getting to the Bottom of It丨Professors Wenyan Chen and Ning Xie: Treatment Options for HER2-Positive Metastatic Breast Cancer After Failure of H-Based Therapy
  • 2026 Northern Breast Cancer Salon · Time & Memory丨Professor Guohong Song: Breaking New Ground and Advancing Further — The Evolution of HER2-Positive Breast Cancer Treatment and the New Treatment Landscape in the ADC Era
  • 2026 Northern Breast Cancer Salon · Time & Memory | Professor Yongmei Yin: Seeing the Subtle to Foresee the Far — The Evolution of Precision Diagnosis and Treatment in Breast Cancer from Molecular Subtyping to Gene-Guided Therapy
Recent Comments
    Archives
    • September 2026
    • August 2026
    • July 2026
    • June 2026
    • May 2026
    • April 2026
    • March 2026
    • February 2026
    • January 2026
    • December 2025
    • November 2025
    • October 2025
    • September 2025
    • August 2025
    • July 2025
    • June 2025
    • May 2025
    • April 2025
    • March 2025
    • February 2025
    • January 2025
    • December 2024
    • November 2024
    • October 2024
    • September 2024
    • August 2024
    • July 2024
    • June 2024
    • May 2024
    • April 2024
    • March 2024
    • February 2024
    • January 2024
    • December 2023
    • November 2023
    • October 2023
    • August 2023
    Categories
    • Artificial intelligence
    • Hematology Frontier
    • Infectious Disease Frontier
    • International Hepatology
    • IOncology
    • Live broadcasting
    • Uncategorized
    • UroStream
    • LinkedIn
    • Twitter
    • Mail
    Related Media:
    Copyright 2026 — MediaMedic. All rights reserved. Blogun WordPress Theme
    Paris, France
    Scroll to Top